down arrow

Aurobindo Pharma

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Drugs
  • ISIN: INE406A01037
  • NSEID: AUROPHARMA
  • BSEID: 524804
INR
1,095.40
37.45 (3.54%)
BSENSE

Apr 11, 12:53 PM

BSE+NSE Vol: 8.81 lacs

Click here to access the older version
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Divi's Lab.
Abbott India
Cipla
Alkem Lab
Glenmark Pharma
Sun Pharma.Inds.
Torrent Pharma
Glaxosmi. Pharma
Aurobindo Pharma
Biocon
Mankind Pharma
Why is Aurobindo Pharma Ltd. ?
1
Poor long term growth as Operating profit has grown by an annual rate 6.08% of over the last 5 years
2
Negative results in Dec 24
  • INTEREST(9M) At Rs 342.22 cr has Grown at 46.77 %
  • OPERATING PROFIT TO INTEREST(Q) Lowest at 13.32 times
  • DEBT-EQUITY RATIO(HY) Highest at 0.27 times
3
Stock is technically in a Bearish range
  • The technical trend has deteriorated from Mildly Bearish on 07-Apr-25
  • The stocks MACD and Bollinger Band technical factors are also Bearish
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Drugs)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Aurobindo Pharma for you?

Medium Risk, Medium Return

Absolute
Risk Adjusted
Volatility
Aurobindo Pharma
-1.2%
-0.06
27.83%
SENSEX
0.45%
0.03
14.48%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
6.99%
EBIT Growth (5y)
6.08%
EBIT to Interest (avg)
32.60
Debt to EBITDA (avg)
1.14
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.86
Tax Ratio
29.69%
Dividend Payout Ratio
8.31%
Pledged Shares
17.83%
Institutional Holding
41.50%
ROCE (avg)
15.20%
ROE (avg)
11.95%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
17
Industry P/E
33
Price to Book Value
2.01
EV to EBIT
13.03
EV to EBITDA
9.87
EV to Capital Employed
1.96
EV to Sales
2.06
PEG Ratio
0.64
Dividend Yield
NA
ROCE (Latest)
15.09%
ROE (Latest)
11.89%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company
ROCE(HY)

Highest at 14.08 %

NET SALES(Q)

Highest at Rs 7,978.52 cr

-11What is not working for the Company
INTEREST(9M)

At Rs 342.22 cr has Grown at 46.77 %

OPERATING PROFIT TO INTEREST(Q)

Lowest at 13.32 times

DEBT-EQUITY RATIO(HY)

Highest at 0.27 times

PBT LESS OI(Q)

Lowest at Rs 1,042.56 cr.

PAT(Q)

At Rs 845.81 cr has Fallen at -7.9 %

Loading Valuation Snapshot...
Here's what is working for Aurobindo Pharma
Net Sales - Quarterly
Highest at Rs 7,978.52 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Here's what is not working for Aurobindo Pharma
Operating Profit to Interest - Quarterly
Lowest at 13.32 times and Fallen
each quarter in the last five quarters
MOJO Watch
The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Interest - Nine Monthly
At Rs 342.22 cr has Grown at 46.77 %
over preceding nine months period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (Rs cr)

Profit Before Tax less Other Income (PBT) - Quarterly
Lowest at Rs 1,042.56 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is negative

PBT less Other Income (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 1,042.56 cr has Fallen at -7.1 %
over average PBT of the previous four quarters of Rs 1,122.68 Cr
MOJO Watch
Near term PBT trend is negative

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 845.81 cr has Fallen at -7.9 %
over average PAT of the previous four quarters of Rs 917.93 Cr
MOJO Watch
Near term PAT trend is negative

PAT (Rs Cr)

Debt-Equity Ratio - Half Yearly
Highest at 0.27 times
in the last five half yearly periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."